Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:KERX

Keryx Biopharmaceuticals (KERX) Stock Price, News & Analysis

Keryx Biopharmaceuticals logo

About Keryx Biopharmaceuticals Stock (NASDAQ:KERX)

Advanced Chart

Key Stats

Today's Range
$2.97
$3.47
50-Day Range
N/A
52-Week Range
$2.47
$5.98
Volume
2.60 million shs
Average Volume
1.69 million shs
Market Capitalization
$344.00 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Keryx Biopharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on providing medicines for patients with kidney disease in the United States. It markets its lead product Auryxia (ferric citrate), an orally available, absorbable, iron-based medicine for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis, as well as for the treatment of iron deficiency anemia in adults with CKD not on dialysis. The company has strategic alliances with Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. for the development and commercialization of ferric citrate in Japan; and with Panion & BF Biotech, Inc. for the development and marketing of ferric citrate. Keryx Biopharmaceuticals, Inc. was founded in 1997 and is headquartered in Boston, Massachusetts.

Receive KERX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Keryx Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

KERX Stock News Headlines

LBTI Lithium & Boron Technology, Inc.
2024 Biopharmaceutical Industry Landscape
Elon’s BIGGEST warning yet?
Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.
Caliway Biopharmaceuticals Co Ltd 6919
XTL Biopharmaceuticals Ltd ADR XTLB
ImmuneOnco Biopharmaceuticals Shanghai Inc (1541)
Q2 2023 Westrock Coffee Co Earnings Call
See More Headlines

KERX Stock Analysis - Frequently Asked Questions

Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) issued its earnings results on Thursday, November, 8th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.01. The biopharmaceutical company earned $28.04 million during the quarter, compared to analysts' expectations of $29.56 million.

Based on aggregate information from My MarketBeat watchlists, some other companies that Keryx Biopharmaceuticals investors own include Synergy Pharmaceuticals (SGYP), Bristol Myers Squibb (BMY), Amyris (AMRS), Gilead Sciences (GILD), Exelixis (EXEL), Meta Platforms (META) and Immunomedics (IMMU).

Company Calendar

Last Earnings
11/08/2018
Today
6/23/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:KERX
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$163.44 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$60.64 million
Price / Cash Flow
N/A
Book Value
($0.12) per share
Price / Book
-28.00

Miscellaneous

Free Float
N/A
Market Cap
$344.00 million
Optionable
Optionable
Beta
2.35
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:KERX) was last updated on 6/23/2025 by MarketBeat.com Staff
From Our Partners